NeuroScientific Biopharmaceuticals Ltd

10:00 AM - 10:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
NeuroScientific Biopharmaceuticals Ltd (NSB) is an Australian-based emerging biotech company developing novel peptide therapeutics for the treatment of neurodegenerative conditions. Our lead drug candidate, EmtinB, is a neuroprotective and neuroregenerative peptide most advanced as a disease modifying treatment for Alzheimer's disease. Additionally, EmtinB is being developed as a treatment for glaucoma due to its ability to protect and regenerate the optic nerve. EmtinB is an agonist of the LRP-1 receptor which is expressed by neuronal cells of both the CNS and PNS, offering a novel MOA for the treatment of neurodegenerative conditions and the potential to be a first-in-class therapeutic. In addition to EmtinB, NSB has a pipeline of therapeutic peptides.
Ticker:
NSB
Exchange:
Australian Securities Exchange
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
EmtinB
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President & CEO
Neuroscientific Biopharmaceuticals